Nijmegen

• Management of Parkinson's disease if levodopa is broken down prematurely Recruiting
  2024-510629-24-00 4 2025-05-14 Parkinson's disease
• Ravulizumab dose optimization Recruiting
  2024-519207-10-00 6 2025-05-12 Paroxysmal nocturnal hemoglobinuria (PNH)
• T-Guard in dcSSc Recruiting
  2024-517283-28-00 9 2025-04-29 diffuse cutaneous systemic sclerosis
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido … Recruiting
  2024-515279-37-00 5 2025-04-17 Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• Transtympanic sodium thiosulfate to prevent cisplatin-related hearing loss, a randomized controlled multicenter phase III trial; The SOUND t … Recruiting
  2023-503313-30-01 5 2025-04-14 Head and Neck squamous cell carcinoma
• Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation-2 (TELSTAR-2): a multicenter randomised clinical … Recruiting
  2024-516068-27-01 5 2025-04-10 cardiopulmonary resuscitation
• A Study to Evaluate the Efficacy, Safety and Tolerability of ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA) Recruiting
  2023-510137-29-01 4 2025-04-09 Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which
• A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting
  2024-512633-32-00 4 2025-04-07 Crohn's disease
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• The MIRAGE study. Use of radioactively labelled deferoxamine for a novel purpose: imaging pulmonary aspergillosis with PET/CT scans. Recruiting
  2023-509744-10-00 4 2025-04-01 Pulmonary aspergillosis
• Efficacy and safety of minidosing lysergic acid diethylamide (LSD) for chronic cluster headache: a randomized placebo-controlled study Recruiting
  2024-520305-39-00 4 2025-04-01 Chronic cluster headache
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 4 2025-03-10 Recurrent Meningioma without local treatment options (Surgery or Radio
• Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting
  2022-500747-21-00 4 2025-02-27 Geographic Atrophy
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• Rifampicin at High Dose for Difficult-to-Treat Tuberculosis (RIAlta) study Recruiting
  2024-519983-42-00 4 2025-02-04 TUBERCULOSIS
• Pred Forte® versus placebo eye drops in chronic central serous chorioretinopathy trial (PICS trial) Recruiting
  2024-511575-15-00 5 2025-01-29 Central serous chorioretinopathy
• CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in p … Recruiting
  2024-512628-12-00 10 2025-01-28 Primary aldosteronism
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col

Showing 193–216 of 568 trials